<DOC>
	<DOCNO>NCT00959231</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy total-body irradiation donor umbilical cord blood transplant help stop growth abnormal cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain abnormal cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study side effect donor umbilical cord blood transplant cyclophosphamide , fludarabine phosphate , total-body irradiation treat patient hematologic disease .</brief_summary>
	<brief_title>Donor Umbilical Cord Blood Transplant After Cyclophosphamide , Fludarabine Phosphate , Total-Body Irradiation Treating Patients With Hematologic Disease</brief_title>
	<detailed_description>OBJECTIVES : - To assess safety efficacy unrelated-donor umbilical cord blood transplantation ( UCBT ) use nonmyeloablative preparative regimen patient hematological disease , multi-institution UK setting . - To confirm unrelated-donor UCBT follow nonmyeloablative conditioning associate consistent durable engraftment patient . - To assess transplant-related mortality day 100 associate nonmyeloablative UCBT patient . - To assess incidence grade II-IV III-IV acute graft-vs-host disease ( GVHD ) patient . - To assess risk relapse progressive disease patient 1 year post transplant nonmyeloablative UCBT . - To assess overall progression-free survival patient 1 year nonmyeloablative UCBT . - To assess immune reconstitution 1 , 2 , 3 , 6 , 12 , 24 month transplant measure quantitative recovery B , T , NK cell ( flow cytometry ) , qualitative recovery T cell ( TREC spectratyping ) , vivo functional T-cell response ( EBV CMV tetramers ) , quantitative immunoglobulin . OUTLINE : This multicenter study . - Reduced-intensity conditioning regimen : Patients receive cyclophosphamide IV 2 hour day -6 fludarabine phosphate IV 1 hour day -6 -2 . Patients undergo single fraction total-body irradiation day -1 . - Umbilical cord blood ( UCB ) transplantation : Patients undergo umbilical cord blood transplantation day 0 . - Graft-vs-host disease prophylaxis : Patients receive cyclosporine IV orally day -3 100 follow taper mycophenolate mofetil IV orally day -3 35 follow taper . Blood bone marrow sample collect periodically analysis . After completion study treatment , patient follow every 3 month year 1 , every 4 month year 2 , every 6 month 5 year , annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis highrisk , advance poorly respond hematological disease reducedintensity hemopoietic stem cell transplantation likely effective Disease status alternative therapy likely achieve cure provide significant prolongation diseasefree survival No chronic myelogenous leukemia first chronic phase respond imatinib refractory blast crisis No acute leukemia morphological relapse/persistent disease ( define &gt; 5 % blast normocellular bone marrow ) No malignant disease refractory progressive salvage therapy No myelofibrosis Donor must match HLAA B antigen level HLADRB1 allelic level No available 56/6 HLAA , B , DRB1 match sibling donor OR 10/10 unrelated volunteer donor PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 60100 % OR Lansky PS 50100 % ( pediatrics ) Transaminases &lt; 5 time upper limit normal ( ULN ) Bilirubin &lt; 3 time ULN Creatinine clearance &gt; 50 mL/min DLCO &gt; 50 % predict No supplemental oxygen requirement Not pregnant nursing Negative pregnancy test No HIV HTLV ( I II ) antibody positivity evidence infection No acquire aplastic anemia No decompensated congestive heart failure uncontrolled arrhythmia leave ventricular ejection fraction â‰¥ 35 % No current active serious infection , particular uncontrolled fungal infection No congenital immune deficiency PRIOR CONCURRENT THERAPY : See Disease Characteristics More 6 month since prior exposure combination chemotherapy OR 1 course induction combination chemotherapy myelodysplastic syndrome acute myeloid leukemia ( please discus study coordinator/s course contain fludarabine ) At least 6 month since prior myeloablative bone marrow transplantation No prior irradiation precludes safe administration additional dose 200 cGy totalbody irradiation No prior autograft</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>hematopoietic/lymphoid cancer</keyword>
</DOC>